CStone Signs $363 Million Deal for Rights to LegoChem ADC Candidate

CStone Pharma of Suzhou acquired global rights (ex-Korea) in a $363.5 million deal to a novel antibody drug conjugate from LegoChem Biosciences. CStone will pay $10 million upfront and up to $353.5 million in milestones. The candidate, LCB71, targets ROR1 (receptor tyrosine kinase-like orphan receptor 1), a high-potential ADC target for various forms of leukemia, non-Hodgkin lymphoma, plus breast, lung, and ovarian cancers. The companies believe LCB71 has first-in-class/best-in-class potential. More details.... Stock Symbols: (HK: 2616) (KOSDAQ: 141080) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.